Dark Horse Consulting and KunTuo Partner to Accelerate CGT Trials
WALNUT CREEK, Calif., and BEIJING, China, May 11, 2026 Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
WALNUT CREEK, Calif., and BEIJING, China, May 11, 2026 Dark Horse Consulting Group (DHCG) and KunTuo Medical Research and...
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
